OVERVIEW

2018 Year in Review™: Reflecting on Recent Evidence for the Treatment of Breast Cancer is organized by Physicians' Education Resource, LLC (PER) and will be held from Apr 09, 2019 - Apr 09, 2020.

Target Audience:
This educational activity is directed toward medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment and management of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate.

Accreditation:
• CME: 2.0

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Explain the design and endpoints of recently reported and ongoing clinical trials evaluating novel strategies for the management of breast cancer
• Detail safety and efficacy data on novel therapeutic strategies that impact the future treatment of breast cancer
• Place emerging evidence into its proper clinical context concerning emerging treatment strategies across the spectrum of disease stages and breast cancer tumor types

Activity Overview:
This Year in Review activity will cover exciting data reported in 2018 at major society meetings with the potential to impact your care of patients with breast cancer. Recent advances in breast cancer include emerging options in targeted therapies, immunotherapeutic strategies, novel combination therapies, and efforts to personalize care. This activity features a panel of experts who will review the key points of clinical trial design and safety, as well as efficacy data, while contextualizing this new information into optimized patient care. Emerging data across the spectrum of breast cancer management will be reviewed and discussed, from early stage to metastatic disease. In addition, our panel of experts will discuss how they are applying this information to their practice right now, as well as its potential future implications.

Benefits of Participation:
• Learn about emerging data for targeted therapies in breast cancer, including AKT and PI3K inhibitors, emerging data for CDK4/6 inhibitors, and an antibody-drug conjugate, as well as new trial data for immunotherapies and PARP inhibitors.
• Benefit from expert guidance on interpreting emerging data and applying new information to the care of your patients with breast cancer.
• Contextualize emerging information on personalizing care based on individual patients with breast cancer and their tumor characteristics.

Additional details will be posted as soon as they are available.